Recombinant L-asparaginase
Recombinant L-asparaginase produced in Pseudomonas fluorescens addresses hypersensitivity issues of E. coli-derived asparaginases by offering a non-cross-reactive treatment for leukemia and lymphoma, ensuring effective and reliable disease management with reduced aggregation.
Patent Information
- Application Number
- JP2026078460
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-07-01
- Filing Date
- 2026-05-07
- Publication Date
- 2026-09-08
AI Technical Summary
Current L-asparaginases derived from E. coli cause adverse hypersensitivity reactions, such as allergic reactions and anaphylactic shock, leading to discontinuation of treatment and poorer prognosis in patients with acute lymphoblastic leukemia and lymphoblastic lymphoma, and are subject to supply shortages.
Development of recombinant L-asparaginase produced in Pseudomonas fluorescens that does not exhibit immunological cross-reactivity with E. coli-derived asparaginases, administered in various dosages and routes to treat diseases like ALL and LBL, optionally as part of a multi-agent chemotherapy regimen.
The recombinant L-asparaginase reduces hypersensitivity reactions, ensures consistent availability, and maintains therapeutic efficacy with minimal aggregation, providing a viable alternative to E. coli-derived asparaginases.